John Souglakos

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Saridaki Zacharenia; Pappas Periklis; Souglakos John; Nikolaidou Martha; Vardakis Nikolaos; Kotsakis Athanasios; Marselos Marios; Georgoulias Vassilis; Mavroudis Dimitris
A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors.
Souglakos J; Philips J; Wang R; Marwah S; Silver M; Tzardi M; Silver J; Ogino S; Hooshmand S; Kwak E; Freed E; Meyerhardt J A; Saridaki Z; Georgoulias V; Finkelstein D; Fuchs C S; Kulke M H; Shivdasani R A
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
Papadaki Chara; Mavroudis Dimitris; Trypaki Maria; Koutsopoulos Anastasios; Stathopoulos Efstathios; Hatzidaki Dora; Tsakalaki Eleftheria; Georgoulias Vassilis; Souglakos John
Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of John Souglakos (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Saridaki Zacharenia; Pappas Periklis; Souglakos John; Nikolaidou Martha; Vardakis Nikolaos; Kotsakis Athanasios; Marselos Marios; Georgoulias Vassilis; Mavroudis Dimitris
A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2009;65(1):121-8.
2009: Souglakos J; Philips J; Wang R; Marwah S; Silver M; Tzardi M; Silver J; Ogino S; Hooshmand S; Kwak E; Freed E; Meyerhardt J A; Saridaki Z; Georgoulias V; Finkelstein D; Fuchs C S; Kulke M H; Shivdasani R A
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
British journal of cancer 2009;101(3):465-72.
2009: Papadaki Chara; Mavroudis Dimitris; Trypaki Maria; Koutsopoulos Anastasios; Stathopoulos Efstathios; Hatzidaki Dora; Tsakalaki Eleftheria; Georgoulias Vassilis; Souglakos John
Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(11):3827-33.
2009: Kalikaki Aristea; Kanaki Maria; Vassalou Helen; Souglakos John; Voutsina Alexandra; Georgoulias Vassilis; Mavroudis Dimitris
DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Clinical lung cancer 2009;10(2):118-23.
2008: Kalikaki A; Koutsopoulos A; Trypaki M; Souglakos J; Stathopoulos E; Georgoulias V; Mavroudis D; Voutsina A
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
British journal of cancer 2008;99(6):923-9.
2008: Souglakos J; Boukovinas I; Taron M; Mendez P; Mavroudis D; Tripaki M; Hatzidaki D; Koutsopoulos A; Stathopoulos E; Georgoulias V; Rosell R
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
British journal of cancer 2008;98(10):1710-5.
2008: Stathopoulos George P; Androulakis Nikos; Souglakos John; Stathopoulos John; Georgoulias Vassilis
Present treatment and future expectations in advanced pancreatic cancer.
Anticancer research 2008;28(2B):1303-8.
2008: Boukovinas Ioannis; Papadaki Chara; Mendez Pedro; Taron Miquel; Mavroudis Dimitris; Koutsopoulos Anastasios; Sanchez-Ronco Maria; Sanchez Jose Javier; Trypaki Maria; Staphopoulos Eustathios; Georgoulias Vassilis; Rosell Rafael; Souglakos John
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
PloS one 2008;3(11):e3695.
2008: Kakolyris S; Souglakos J; Polyzos A; Ardavanis A; Ziras N; Athanasiadis A; Varthalitis I; Amarantidis K; Tsousis S; Vamvakas L; Vardakis N; Georgoulias V;
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Oncology 2008;74(1-2):31-6.
2007: Pallis A G; Voutsina A; Kalikaki Ar; Souglakos J; Briasoulis E; Murray S; Koutsopoulos A; Tripaki M; Stathopoulos E; Mavroudis D; Georgoulias V
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.
British journal of cancer 2007;97(11):1560-6.
2007: Koutsopoulos Anastassios V; Mavroudis Dimitris; Dambaki Konstantina I; Souglakos John; Tzortzaki Eleni G; Drositis John; Delides George S; Georgoulias Vassilis; Stathopoulos Efstathios N
Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome.
Lung cancer (Amsterdam, Netherlands) 2007;57(2):193-200.
2007: Gkioulbasanis I; Souglakos J; Vardakis N; Kotsakis A; Saridaki Z; Kentepozidis N; Polyzos A; Giassas S; Ignatiadis M; Bozionelou V; Christophylakis C; Georgoulias V
Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2007;12(2):197-202.
2007: Souglakos J; Kalykaki A; Vamvakas L; Androulakis N; Kalbakis K; Agelaki S; Vardakis N; Tzardi M; Kotsakis A P; Gioulbasanis J; Tsetis D; Sfakiotaki G; Chatzidaki D; Mavroudis D; Georgoulias V
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(2):305-10.
2007: Pallis A G; Christofillakis Ch; Tselepatiotis E; Agelaki S; Vamvakas L; Souglakos J; Vardakis N; Kalykaki A; Kotsakis A; Argiraki A; Mavroudis D; Georgoulias V
Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.
Lung cancer (Amsterdam, Netherlands) 2007;55(1):101-7.
2007: Emmanouilides Christos; Sfakiotaki Georgia; Androulakis Nikolaos; Kalbakis Kostas; Christophylakis Charalambos; Kalykaki Antonia; Vamvakas Lambros; Kotsakis Athanasios; Agelaki Sofia; Diamandidou Eleni; Touroutoglou Nikolaos; Chatzidakis Adam; Georgoulias Vassilis; Mavroudis Dimitris; Souglakos John
Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study.
BMC cancer 2007;7():91.
2007: Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Digestive diseases (Basel, Switzerland) 2007;25(1):100-5.
2007: Souglakos John
Genetic alterations in sporadic and hereditary colorectal cancer: implementations for screening and follow-up.
Digestive diseases (Basel, Switzerland) 2007;25(1):9-19.
2006: Souglakos J; Androulakis N; Syrigos K; Polyzos A; Ziras N; Athanasiadis A; Kakolyris S; Tsousis S; Kouroussis Ch; Vamvakas L; Kalykaki A; Samonis G; Mavroudis D; Georgoulias V
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).
British journal of cancer 2006;94(6):798-805.
2006: Souglakos John; Vamvakas Lambros; Apostolaki Stella; Perraki Maria; Saridaki Zacharenia; Kazakou Irine; Pallis Athanasios; Kouroussis Charalambos; Androulakis Nikos; Kalbakis Kostas; Millaki Georgia; Mavroudis Dimitris; Georgoulias Vassilis
Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.
Breast cancer research : BCR 2006;8(4):R36.
2005: Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kouroussis Ch; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: A phase II trial.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2005;10(1):47-52.
2005: Souglakos J; Pallis A; Kakolyris S; Mavroudis D; Androulakis N; Kouroussis C; Agelaki S; Xenidis N; Milaki G; Georgoulias V
Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
Oncology 2005;69(5):384-90.
2005: Souglakos John; Kakolyris Stylianos; Vardakis Nikolaos; Androulakis Nikolaos; Mavroudis Dimitrios; Vamvakas Lambos; Kouroussis Charalambos; Agelaki Sophia; Saridaki Zacharenia; Georgoulias Vassilis
A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors.
Cancer investigation 2005;23(6):505-10.
2004: Kouroussis Charalambos; Kalbakis Konstantinos; Androulakis Nikolaos; Agelaki Sophia; Vamvakas Lambros; Malas Konstantinos; Souglakos John; Vardakis Nikolaos; Georgoulias Vassilis
A dose escalation study of leucovorin (LV) and 48-hour continuous infusion of 5-fluorouracil in combination with cyclophosphamide and vinorelbine in pretreated patients with metastatic breast cancer.
Anticancer research 2004;24(6):4217-21.
2004: Taron Miquel; Rosell Rafael; Felip Enriqueta; Mendez Pedro; Souglakos John; Ronco Maria Sanchez; Queralt Cristina; Majo Joaquim; Sanchez Jose Miguel; Sanchez Jose Javier; Maestre Jose
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
Human molecular genetics 2004;13(20):2443-9.
2004: Souglakos J; Syrigos K; Potamianou A; Polyzos A; Boukovinas I; Androulakis N; Kouroussis Ch; Vardakis N; Christophilakis Ch; Kotsakis A; Georgoulias V
Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(8):1204-9.
2004: Kouroussis Charalambos; Mavroudis Dimitris; Kakolyris Stylianos; Voloudaki Argyro; Kalbakis Konstantinos; Souglakos John; Agelaki Sophia; Malas Konstantinos; Bozionelou Vassiliki; Georgoulias Vassilis
High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.
Lung cancer (Amsterdam, Netherlands) 2004;44(3):363-8.
2004: Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Samonis G; Vardakis N; Amarantidis K; Agelaki S; Mavroudis D; Xenidis N; Georgoulias V
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Oncology 2004;66(4):253-9.
2003: Souglakos John; Androulakis Nikolaos; Mavroudis Dimitrios; Kourousis Charalabos; Kakolyris Stylianos; Vardakis Nikolaos; Kalbakis Konstantinos; Pallis Athanasios; Ardavanis Alexandros; Varveris Charalabos; Georgoulias Vassilios
Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer.
International journal of radiation oncology, biology, physics 2003;56(5):1284-7.
2003: Pallis A G; Mavroudis D; Androulakis N; Souglakos J; Kouroussis C; Bozionelou V; Vlachonikolis I G; Georgoulias V
ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
Lung cancer (Amsterdam, Netherlands) 2003;40(3):301-7.
2003: Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(2):304-12.
2003: Kouroussis Charalambos; Agelaki Sophia; Mavroudis Dimitris; Kakolyris Stylianos; Androulakis Nick; Kalbakis Kostas; Souglakos John; Mallas Kostas; Bozionelou Vassiliki; Pallis Athanasios; Adamtziki Helen; Georgoulias Vassilis
A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.
Anticancer research 2003;23(1B):785-91.
2002: Kouroussis Charalambos; Souglakos John; Mavroudis Dimitris; Papadouris Savvakis; Kakolyris Stylianos; Agelaki Sophia; Kalbakis Kostas; Panopoulos Christos; Vardakis Nikos; Sarra Evanthia; Georgoulias Vassilis
Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).
American journal of clinical oncology 2002;25(6):627-31.
2002: Giannakakis Theodore; Kakolyris Stelios; Theodoropoulos Elias; Kouroussis Charalambos; Michailakis Emmanuel; Papadouris Savvakis; Tsitoura Miranda; Kalbakis Kostas; Souglakos John; Agelaki Sohia; Vardakis Nikos; Georgoulias Vassilis
A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer.
Anticancer research 2002;22(6B):3743-8.
2002: Androulakis N; Kouroussis C; Mavroudis D; Kakolyris S; Souglakos J; Agelaki S; Kalbakis K; Malas K; Pallis A; Samonis G; Georgoulias V
Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(15):1992-7.
2002: Mavroudis D; Veslemes M; Kouroussis Ch; Tzanakis N; Ferdoutsis E; Toumbis M; Ziotopoulos P; Agelidou M; Tselepatiotis E; Kalbakis K; Souglakos J; Magkanas E; Samonis G; Georgoulias V;
Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
Lung cancer (Amsterdam, Netherlands) 2002;38(1):59-63.
2002: Souglakos John; Kotsakis Athanaslos; Kouroussis Charalambos; Kakolyris Stylianos; Mavroudis Dimitrios; Kalbakis Konstadinos; Agelaki Sofia; Vlachonikolis John; Georgoulias Vassilis; Samonis George
Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors.
Cancer 2002;95(6):1326-33.
2002: Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V
Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(11):2651-7.
2002: Vamvakas L; Kakolyris S; Kouroussis C; Kandilis K; Mavroudis D; Ziras N; Androulakis N; Kalbakis K; Sarra E; Souglakos J; Georgoulias V;
Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.
American journal of clinical oncology 2002;25(1):65-70.
2002: Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Oncology 2002;62(3):216-22.
2002: Kosmas C; Agelaki S; Giannakakis Th; Mavroudis D; Kouroussis Ch; Kalbakis K; Papadouris S; Souglakos J; Malamos N; Georgoulias V
Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer.
Oncology 2002;62(2):103-9.
2001: Agelaki S; Bania H; Kouroussis C; Blazoyiannakis G; Souglakos J; Tsiafaki X; Kalbakis K; Rapti A; Androulakis N; Georgoulias V; Papadakis E
Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study.
Lung cancer (Amsterdam, Netherlands) 2001;34 Suppl 4():S77-80.
2001: Kakolyris S; Kouroussis C; Souglakos J; Agelaki S; Kalbakis K; Vardakis N; Vamvakas L; Georgoulias V
Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2001;34 Suppl 4():S71-6.
2001: Kakolyris S; Giatromanolaki A; Koukourakis M; Powis G; Souglakos J; Sivridis E; Georgoulias V; Gatter K C; Harris A L
Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(10):3087-91.
2001: Papakostas P; Kouroussis C; Androulakis N; Samelis G; Aravantinos G; Kalbakis K; Sarra E; Souglakos J; Kakolyris S; Georgoulias V
First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study.
European journal of cancer (Oxford, England : 1990) 2001;37(15):1833-8.
2001: Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
British journal of cancer 2001;85(6):798-802.
2001: Kouroussis C; Kakolyris S; Mavroudis D; Androulakis N; Kalbakis K; Agelaki S; Sarra E; Souglakos J; Christodoulakis M; Samonis G; Georgoulias V
A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors.
American journal of clinical oncology 2001;24(4):404-7.
2001: Kakolyris S; Mavroudis D; Tsavaris N; Souglakos J; Tsiafaki P; Kalbakis K; Agelaki S; Androulakis N; Georgoulias V
Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(2):193-7.
2001: Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Oncology 2001;61(4):265-70.
2001: Kouroussis C; Souglakos J; Kakolyris S; Mavroudis D; Malamos N; Kalbakis K; Androulakis N; Agelaki A; Vardakis N; Samonis G; Georgoulias V
Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study.
Oncology 2001;61(1):36-41.
2001: Agelaki S; Bania H; Kouroussis C; Blazoyiannakis G; Souglakos J; Tsiafaki X; Harpidou A; Kalbakis K; Rapti A; Androulakis N; Sarra E; Georgoulias V; Papadakis E
Vinorelbine-based regimens as salvage treatment in patients with advanced non-small cell lung cancer: two parallel multicenter phase II trials.
Oncology 2001;60(3):235-41.
2001: Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Mavroudis D; Kalbakis K; Kotsakis A; Vardakis N; Koukourakis M; Romanos J; Georgoulias V
A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer.
Oncology 2001;60(3):207-13.
2000: Kakolyris S; Souglakos J; Agelaki S; Kourousis C H; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Lung cancer (Amsterdam, Netherlands) 2000;30(3):193-8.
2000: Kotsakis A; Sarra E; Peraki M; Koukourakis M; Apostolaki S; Souglakos J; Mavromanomakis E; Vlachonikolis J; Georgoulias V
Docetaxel-induced lymphopenia in patients with solid tumors: a prospective phenotypic analysis.
Cancer 2000;89(6):1380-6.
2000: Mavroudis D; Kourousis C; Androulakis N; Kalbakis K; Agelaki S; Kakolyris S; Souglakos J; Sarra E; Vardakis N; Hatzidaki D; Sarmonis G; Georgoulias V
Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.
American journal of clinical oncology 2000;23(4):341-4.
2000: Kakolyris S; Kouroussis C; Kalbakis K; Mavroudis D; Souglakos J; Nvardakis; Kremos S; Georgoulias V
Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(6):757-60.
2000: Kouroussis C; Samonis G; Androulakis N; Souglakos J; Voloudaki A; Dimopoulos M A; Kotsakis T; Kakolyris S; Kalbakis K; Georgoulias V
Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases.
American journal of clinical oncology 2000;23(3):309-13.
2000: Mavroudis D; Kourousis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Samonis G; Georgoulias V
Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report.
Seminars in oncology 2000;27(1 Suppl 2):25-30.
2000: Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2000;46(6):488-92.
1999: Kouroussis C; Georgoulias V; Souglakos J; Simvoulakis E; Karabekios S; Samonis G
Spontaneous spondylodiscitis caused by Klebsiella pneumoniae.
Infection 1999;27(6):368-9.
1999: Kouroussis C; Androulakis N; Kakolyris S; Souglakos J; Kotsakis T; Mavroudis D; Katsogridakis K; Vardakis N; Hatzidaki D; Samonis G; Vlachonikolis J; Georgoulias V
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):862-9.
1998: Kourousis C; Androulakis N; Kakolyris S; Souglakos J; Maltezakis G; Metaxaris G; Chalkiadakis G; Samonis G; Vlachonikolis J; Georgoulias V
First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
Cancer 1998;83(10):2083-90.
1998: Androulakis N; Kouroussis C; Kakolyris S; Tzannes S; Papadakis E; Papadimitriou C; Geroyianni A; Georgopoulou T; Dimopoulou I; Souglakos J; Kotsakis A; Vardakis N; Hatzidaki D; Georgoulias V
Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(10):1127-30.
1997: Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Seminars in oncology 1997;24(4 Suppl 14):S14-9-S14-14.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

John Souglakos

Research Profile (preview)

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of John Souglakos (preview)

All Publications